Pharmacogenomics in psychiatry: The relevance of receptor and transporter polymorphisms

British Journal of Clinical Pharmacology

Volumn 77, Issue 4, 2014, Pages 654-672

  Reynolds, Gavin P ^a   McGowan, Olga O ^b   Dalton, Caroline F ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b WISHAW GENERAL HOSPITAL   (United Kingdom)

Author keywords

antidepressant drugs; antipsychotic drugs; bipolar illness; depression; gene; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOLAMINE; CITALOPRAM; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; GLUTAMIC ACID; HALOPERIDOL; ILOPERIDONE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SERTRALINE; NEUROTRANSMITTER TRANSPORTER; PSYCHOTROPIC AGENT;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DNA METHYLATION; DOPAMINE RECEPTOR BLOCKING; DRUG MECHANISM; DRUG RESPONSE; EPIGENETICS; GABAERGIC SYSTEM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERPROLACTINEMIA; MANIA; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NEUROCHEMISTRY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR GENE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; GENETICS; MENTAL DISORDERS;

EPIGENOMICS; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MENTAL DISORDERS; NEUROTRANSMITTER TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; RECEPTORS, NEUROTRANSMITTER;

EID: 84897894099     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12312     Document Type: Article

References (133)

1. Pickar D, Rubinow K,. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001; 22: 75-83.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
3. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142.
4. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch KP,. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624.
5. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D,. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-826.
6. Battersby S, Ogilvie AD, Smith CA, Blackwood DH, Muir WJ, Quinn JP, Fink G, Goodwin GM, Harmar AJ,. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet 1996; 6: 177-181.
7. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M,. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
8. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ,. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
9. Serretti A, Kato M, De Ronchi D, Kinoshita T,. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-257.
10. Taylor MJ, Sen S, Bhagwagar Z,. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 2010; 68: 536-543.
11. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ,. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
12. Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, Kim JW, Carroll BJ, Kim DK,. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 2013; 225: 283-290.
13. Porcelli S, Fabbri C, Serretti A,. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239-258.
14. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH,. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9: 433-441.
15. Niitsu T, Fabbri C, Bentini F, Serretti A,. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 35: 183-194.
16. Tharoor H, Kotambail A, Jain S, Sharma PS, Satyamoorthy K,. Study of the association of serotonin transporter triallelic 5-HTTLPR and STin2 VNTR polymorphisms with lithium prophylaxis response in bipolar disorder. Psychiatr Genet 2013; 23: 77-81.
17. Lin E, Chen PS,. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008; 9: 935-946.
18. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF,. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163-1169.
19. Safarinejad MR,. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int 2010; 105: 73-78.
20. Dombrovski AY, Mulsant BH, Ferrell RE, Lotrich FE, Rosen JI, Wallace M, Houck PR, Mazumdar S, Pollock BG,. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010; 25: 37-45.
21. Rotberg B, Kronenberg S, Carmel M, Frisch A, Brent D, Zalsman G, Apter A, Weizman A,. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and Adolescents with depression and anxiety disorders. J Child Adolesc Psychopharmacol 2013; 23: 117-122.
22. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR,. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003; 23: 8788-8799.
23. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR,. Association of the C (-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 2004; 7: 501-506.
24. Drago A, Ronchi DD, Serretti A,. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol 2008; 11: 701-721.
25. Yevtushenko OO, Oros MM, Reynolds GP,. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 2010; 123: 308-311.
26. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L,. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006; 163: 1826-1829.
27. 1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008; 22: 904-909.
28. Mössner R, Schuhmacher A, Kühn KU, Cvetanovska G, Rujescu D, Zill P, Quednow BB, Rietschel M, Wölwer W, Gaebel W, Wagner M, Maier W,. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19: 91-94.
29. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L, Reynolds GP,. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol 2012; 26: 349-359.
30. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ,. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004; 56: 406-410.
31. 2A receptor gene. Am J Psychiatry 2002; 159: 1593-1595.
32. Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, Bloom D, Labelle A, Lalonde P, Fortin D, Alda M, Palmour R, Rouleau GA,. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24: 141-146.
33. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW,. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-99.
34. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB,. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009; 17: 946-957.
35. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H,. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
36. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS,. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005; 52: 155-162.
37. Gunes A, Scordo MG, Jaanson P, Dahl ML,. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 2007; 190: 479-484.
38. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F,. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425.
39. Zhang JP, Malhotra AK,. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7: 9-37.
40. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B,. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152: 408-413.
41. Reynolds GP, Kirk SL,. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010; 125: 169-179.
42. Reynolds GP, Zhang ZJ, Zhang XB,. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
43. Reynolds GP,. Pharmacogenetic aspects of antipsychotic drug-induced weight gain-a critical review. Clin Psychopharmacol Neurosci 2012; 10: 71-77.
44. Hill MJ, Reynolds GP,. Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics 2011; 12: 727-734.
45. Templeman LA, Reynolds GP, Arranz B, San L,. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics 2005; 15: 195-200.
46. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S,. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69: 1416-1422.
47. Zlojutro M, Manz N, Rangaswamy M, Xuei X, Flury-Wetherill L, Koller D, Bierut LJ, Goate A, Hesselbrock V, Kuperman S, Nurnberger J Jr, Rice JP, Schuckit MA, Foroud T, Edenberg HJ, Porjesz B, Almasy L,. Genome-wide association study of theta band event-related oscillations identifies serotonin receptor gene HTR7 influencing risk of alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 44-58.
48. Opmeer EM, Kortekaas R, Aleman A,. Depression and the role of genes involved in dopamine metabolism and signalling. Prog Neurobiol 2010; 92: 112-133.
49. Wu J, Xiao H, Sun H, Zou L, Zhu LQ,. Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol Neurobiol 2012; 45: 605-620.
50. Faludi G, Gonda X, Bagdy G, Dome P,. Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: a brief review. Neuropsychopharmacol Hung 2012; 14: 221-229.
51. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA,. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
52. Cohen MX, Young J, Baek JM, Kessler C, Ranganath C,. Individual differences in extraversion and dopamine genetics predict neural reward responses. Brain Res Cogn Brain Res 2005; 25: 851-861.
53. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, Sedvall GC,. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
54. Arinami T, Gao M, Hamaguchi H, Toru M,. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582.
55. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H, Kaneko S, Inoue Y, Otani K,. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545-550.
56. Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL,. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005; 181: 179-187.
57. Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, Kennedy JL,. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006; 16: 248-259.
58. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK,. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163: 529-531.
59. Zhang JP, Lencz T, Malhotra AK,. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010; 167: 763-772.
60. Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, Lieberman JA, Kennedy JL,. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2012; 12: 156-164.
61. Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, Malhotra AK,. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 2010; 20: 569-572.
62. Cookson J, Hodgson R, Wildgust HJ,. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012; 26 (5 Suppl.): 42-51.
63. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, Noble EP,. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185: 147-151.
64. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA,. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009; 19: 373-382.
65. Zhang XR, Zhang ZJ, Zhu RX, Yuan YG, Jenkins TA, Reynolds GP,. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011; 12: 1127-1136.
66. Lopez-Rodriguez R, Roman M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F,. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 2011; 31: 555-562.
67. Lundstrom K, Turpin MP,. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068-1072.
68. Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S,. Aschauer HN Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999; 10: 17-20.
69. Szekeres G, Kéri S, Juhász A, Rimanõczy A, Szendi I, Czimmer C, Janka Z,. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 1-5.
70. Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, Breier A, Pickar D,. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998; 3: 72-75.
71. Kim B, Choi EY, Kim CY, Song K, Joo YH,. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008; 23: 61-67.
72. Steen VM, Lovlie R, MacEwan T, McCreadie RG,. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
73. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ,. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44: 95-98.
74. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F,. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
75. Bakker PR, van Harten PN, van Os J,. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185-192.
76. Tsai HT, North KE, West SL, Poole C,. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 57-66.
77. Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, Stroup TS, Sullivan PF,. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336-340.
78. Willeit M, Praschak-Rieder N,. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage 2010; 53: 878-892.
79. Roman T, Rohde LA, Hutz MH,. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit- hyperactivity disorder. Am J Pharmacogenomics 2004; 4: 83-92.
80. Cheon KA, Ryu YH, Kim JW, Cho DY,. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 2005; 15: 95-101.
81. Kambeitz J, Romanos M, Ettinger U,. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J 2013; Apr 16. doi: 10.1038/tpj.2013.9. [Epub ahead of print].
82. Xu M, Xing Q, Li S, Zheng Y, Wu S, Gao R, Yu L, Guo T, Yang Y, Liu J, Zhang A, Zhao X, He G, Zhou J, Wang L, Xuan J, Du J, Li X, Feng G, Lin Z, Xu Y, St Clair D, Lin Z, He L,. Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1026-1032.
83. Zhang A, Xing Q, Wang L, Du J, Yu L, Lin Z, Li X, Feng G, He L,. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007; 8: 1337-1345.
84. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J,. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 2007; 7: 48-55.
85. Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, Kerwin RW,. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000; 280: 65-68.
86. Cheng C, Chiu HJ, Loh W, Chan CH, Hwu TM, Liu YR, Lan TH,. Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 205-210.
87. Talmud PJ, Cooper JA, Gaunt T, Holmes MV, Shah S, Palmen J, Drenos F, Shah T, Kumari M, Kivimaki M, Whittaker J, Lawlor DA, Day IN, Hingorani AD, Casas JP, Humphries SE,. Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies. Diabetologia 2011; 54: 1710-1719.
88. Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ, de Leon J,. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008; 23: 107-114.
89. Liu YR, Loh EW, Lan TH, Chen SF, Yu YH, Chang YH, Huang CJ, Hu TM, Lin KM, Yao YT, Chiu HJ,. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010; 10: 30-39.
90. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ,. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005; 112: 1463-1468.
91. Sickert L, Müller DJ, Tiwari AK, Shaikh S, Zai C, De Souza R, De Luca V, Meltzer HY, Lieberman JA, Kennedy JL,. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009; 10: 1169-1176.
92. De Luca V, Souza RP, Viggiano E, Sickert L, Teo C, Zai C, Tiwari AK, Müller DJ, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL,. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Hum Psychopharmacol 2011; 26: 386-391.
93. Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA,. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 218-224.
94. da Silva TL, Pianca TG, Roman T, Hutz MH, Faraone SV, Schmitz M, Rohde LA,. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm 2008; 115: 341-345.
95. Cheon KA, Cho DY, Koo MS, Song DH, Namkoong K,. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry 2009; 65: 564-570.
96. Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ,. Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction? J Child Adolesc Psychopharmacol 2012; 22: 343-352.
97. Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Yang YH, Kim HJ, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH,. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol 2013; 33: 356-362.
98. Contini V, Victor MM, Cerqueira CC, Polina ER, Grevet EH, Salgado CA, Karam RG, Vitola ES, Belmonte-de-Abreu P, Bau CH,. Adrenergic alpha2A receptor gene is not associated with methylphenidate response in adults with ADHD. Eur Arch Psychiatry Clin Neurosci 2011; 261: 205-211.
99. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB,. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161: 1575-1580.
100. Houston JP, Zou W, Aris V, Fijal B, Chen P, Heinloth AN, Martinez J,. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder. Psychiatry Res 2012; 200: 63-65.
101. Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, Yamashita M, Nonen S, Azuma J, Kinoshita T,. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 2008; 28: 518-524.
102. Kantrowitz J, Javitt DC,. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012; 25: 96-102.
103. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF,. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002; 7 (Suppl. 1): S71-80.
104. Mallolas J, Hurtado O, Castellanos M, Blanco M, Sobrino T, Serena J, Vivancos J, Castillo J, Lizasoain I, Moro MA, Dávalos A,. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med 2006; 203: 711-717.
105. Dallaspezia S, Poletti S, Lorenzi C, Pirovano A, Colombo C, Benedetti F,. Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder. Mol Diagn Ther 2012; 16: 303-309.
106. Walitza S, Wendland JR, Gruenblatt E, Warnke A, Sontag TA, Tucha O, Lange KW,. Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolesc Psychiatry 2010; 19: 227-235.
107. Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, Choi JS, Kim B, Kang DH, Oh S, Park T, Hong KS,. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 2009; 66: 1233-1241.
108. Hirunsatit R, George ED, Lipska BK, Elwafi HM, Sander L, Yrigollen CM, Gelernter J, Grigorenko EL, Lappalainen J, Mane S, Nairn AC, Kleinman JE, Simen AA,. Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates SLC6A1 GABA transporter promoter activity. Pharmacogenet Genomics 2009; 19: 53-65.
109. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ,. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007; 164: 1181-1188.
110. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Müller-Myhsok B, Holsboer F, Binder EB,. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35: 727-740.
111. Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J,. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology 2012; 65: 70-75.
112. Pu M, Zhang Z, Xu Z, Shi Y, Geng L, Yuan Y, Zhang X, Reynolds GP,. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics 2013; 14: 277-288.
113. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH,. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009; 14: 804-819.
114. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C,. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009; 70: 801-809.
115. Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP,. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry 2012; 73: 367-371.
116. Chaki S,. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol 2010; 639: 59-66.
117. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP,. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009; 9: 311-318.
118. Bishop JR, Miller D, Ellingrod VL, Holman T,. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol 2011; 26: 28-34.
119. Bishop JR, Ellingrod VL, Moline J, Miller D,. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005; 77: 253-260.
120. Crisafulli C, Chiesa A, De Ronchi D, Han C, Lee SJ, Park MH, Patkar AA, Pae CU, Serretti A,. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neurosci Lett 2012; 506: 170-174.
121. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, Sachs GS, Nimgaonkar V, Scolnick EM, Gurling H, Sklar P, Purcell S,. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718-725.
122. Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvoráková M, Libigerová E, Vojtěchovský M, Zvolský P, Nilsson A, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Robertson C, Rouleau GA, Alda M,. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci 2000; 25: 353-358.
123. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T,. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317-323.
124. Giegling I, Drago A, Dolžan V, Plesničar BK, Schäfer M, Hartmann AM, Sander T, Toliat MR, Möller HJ, Stassen HH, Rujescu D, Serretti A,. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics 2011; 21: 206-216.
125. Nemeroff CB, Vale WW,. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66 (Suppl. 7): 5-13.
126. Mandelli L, Marino E, Pirovano A, Calati R, Zanardi R, Colombo C, Serretti A,. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol 2009; 19: 64-67.
127. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W, Zobel A, Hauser J, Souery D, Placentino A, Larsen ER, Dmitrzak-Weglarz M, Gupta B, Hoda F, Craig I, McGuffin P, Farmer AE, Aitchison KJ,. Interaction between serotonin transporter gene variants and life
128. McCormick CM, Mathews IZ,. Development, hypothalamic-pituitary-adrenal function, and programming of adult learning and memory. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 756-765.
129. Vijayendran M, Beach SR, Plume JM, Brody GH, Philibert RA,. Effects of genotype and child abuse on DNA methylation and gene expression at the serotonin transporter. Front Psychiatry 2012; 3: 55.
130. Beach SR, Brody GH, Todorov AA, Gunter TD, Philibert RA,. Methylation at SLC6A4 is linked to family history of child abuse: an examination of the Iowa Adoptee sample. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 710-713.
131. Kang HJ, Kim JM, Stewart R, Kim SY, Bae KY, Kim SW, Shin IS, Shin MG, Yoon JS,. Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 44: 23-28.
132. Sales AJ, Biojone C, Terceti MS, Guimarães FS, Gomes MV, Joca SR,. intra-hippocampal administration of DNA methylation inhibitors. Br J Pharmacol 2011; 164: 1711-1721.
133. Melas PA, Rogdaki M, Ösby U, Schalling M, Lavebratt C, Ekström TJ,. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J 2012; 26: 2712-2718.